The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000901303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/05/2026
Date registered
Help: Date registered
22/07/2026
Date last updated
Help: Date last updated
22/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/07/2026
Date results provided
Help: Date results provided
22/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparison of medication error rate between a doctor-pharmacist collaborative model of prescribing and usual medical prescribing, within the perioperative setting of a non-tertiary hospital.
Scientific title
A comparison of the medication error rate between a doctor-pharmacist collaborative model and the usual medical model for prescribing of patients’ admission medication orders, in adult patients booked for elective surgery, within a non-tertiary hospital.
Additional trial identifiers [1] 317250 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Medication Error 341862 0
Condition category
Condition code
Surgery 337929 337929 0 0
Other surgery
Public Health 338137 338137 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure

What is the intervention:
A doctor-pharmacist collaborative prescribing model of care. This model of care requires a cooperative practice relationship between a pharmacist, with legal authority to prescribe medications. The physician diagnoses and makes initial treatment decisions for the patient (in our case this meant that the physician determines what elective surgical treatment is required), and the pharmacist initiates, modifies and continues or discontinues medications as appropriate to achieve the agreed patient outcomes. (in our case safe medication management during the perioperative period). An example of this modifying diabetic medication dose during the clear fluid period with bowel prepartion prior to colonoscopy.

Who delivers it and their relevant expertise:
The pharmacist prescriber was an experienced pharmacist (18 years of experience) who completed an extensive prescribing training program. The prescribing course content and competency was developed and assessed by Queensland University of Technology (QUT). The course was created to provide training for allied health clinicians to prescribe, as part of a research pilot. Course components reflected similar curriculum to the education and training programs available to prepare pharmacist prescribers in the UK by the General Pharmaceutical Council (GPhC) and in New Zealand by the Pharmacy Council of New Zealand. The QUT course was six months in duration plus 120 hours of learning in practice. The framework and competency for the learning in practice component was extensive. Supervision and sign off for the learning in practice component was delivered by designated medical practitioners at the hospital site. The pharmacist prescriber was assessed as competent to prescribe safely and effectively within the agreed scope of practice in clinic, prior to the study commencing. They received orientation education regarding hospital prescribing guidelines, including for perioperative medication management guidelines.

How it is delivered (e.g. face to face, online, group, individual):
The pharmacist prescriber delivered care face to face with individual patients

How often and for how long & where it was delivered:
The pharmacist prescriber delivered care to patients on one occasion only, at the time of the patient's consult in the pre-admission clinic (PAC) at Redland Hospital. The The allocated time for consults is approx approx 30 mins. For intervention patients ,the order of consultaion with other clinicians through PAC required them to see the prescribing pharmacist before any physician consults. This was so that the physician (Anaesthetist +/- Surgical resident) could review the prescribing pharmacist's medication management plan. This was an intentional extra safety step built in to the trial protocol. The patient saw each clinician in the PAC once only.
Prescribing by the pharmacist prescriber was completed after the patient consultation was completed in the PAC. The pharmacist prescriber prescribed the admission medications on to the patient's inpatient medication chart (this included home medications and surgical prophylaxis only), ready for admission, in the PAC setting, on the same day as the patient attended PAC.

Adherence (e.g. reminders, monitoring):
The pharmacist prescriber to assess the patient's understanding and ability to adhere to the perioperative medication plan at the end of the consult. The patient would also be provided with a written summary of the plan.
A local trial steering committee was implemented as the central governance structure for the trial. Both the principal and associate investigators participated in this committee. The committee reviewed the trial progress and any risks arising from the trial; review and monitoring of incident reporting associated with trial participants; provision of updates to the local Patient Safety & Quality committee. Additionally, ward pharmacists were advised and encouraged to report any medication errors that may be attributed to the trial to the Director of Pharmacy, independently of the pharmacist prescriber.




Intervention code [1] 334023 0
Prevention
Description of the comparator or control
The doctor prescribers were mostly at resident level (postgraduate year 2 at varying periods of the academic year). They received orientation education (approx 60mins in duration) regarding hospital prescribing guidelines, including for perioperative medication management guidelines. They also attended an information session (approx 30mins in duration) to enable awareness of the trial, an overview of what was being evaluated, and to explain what their responsibilities were throughout the trial

Prescribing of home medications was done by the surgical resident doctors. They prescribed the medication orders after the patient consultation in the pre-admission clinic (PAC), and mostly on the day of hospital admission, within the inpatient setting. If patients attended PAC on the one session once a week that the surgical resident attended, then they would have one encounter with the surgical resident.
The surgical resident doctor consult included the following:
• taking a medical and surgical history
• education on surgical procedure
• discussion of any surgical risks or issues raised by the patient
• confirmation that the consent for surgery has been completed
• cardiac assessment, including electrocardiogram (ECG) analysis
• organisation of chest X-Rays and pathology
• respiratory function and spirometry analysis
• verbal instructions on medication plan
The consult with the surgical resident took approx 20mins.

As part of usual care, patients taking high risk medication would additionally see the PAC Pharmacist (ie. non prescribing pharmacist) who would provide comprehensive medication information and education, including written instructions.

For all other patients, they had no encounter with the surgical resident until they admitted to hospital. These patients were seen in PAC by the Anaesthetist +/- PAC pharmacist. The Anaesthetic consultation in PAC included:
• taking a medical and surgical history (unless already seen by surgical doctor)
• taking a medication history (for patients not meeting PAC Pharmacist selection)
• providing a perioperative medication plan (for patients not meeting PAC Pharmacist selection)
• previous surgical and anaesthetic experiences
• family history of surgical and anaesthetic experience
• airway assessment
• dental assessment
• reflux assessment
• exercise tolerance
• cardiac assessment, including ECG analysis
• respiratory function and spirometry analysis
• discussion of all anaesthetic options
• discussion of any anaesthetic risks
The consult with the Anaesthetist took approx 30mins.

Surgical antibiotic prophylaxis medication orders were prescribed as a once off, by experienced anaesthetic doctors (either Registrar or consultant level) in the operating theatre

Control group
Active

Outcomes
Primary outcome [1] 345374 0
Medication discrepancies
Timepoint [1] 345374 0
On the day the patient is admitted to hospital
Primary outcome [2] 345375 0
Prescribing communication errors rate
Timepoint [2] 345375 0
On the day the patient is admitted to hospital
Primary outcome [3] 345827 0
Unintentional medication omissions
Timepoint [3] 345827 0
On the day the patient is admitted to hospital
Secondary outcome [1] 461461 0
Compliance rate for surgical antibiotic prophylaxis against local antimicrobial (AMS) prescribing guidelines
Timepoint [1] 461461 0
Pre or post surgical period applicable to specific requirement of antiobiotic regime.
Secondary outcome [2] 461462 0
Amount of saved doctors' (anaesthetists') time.
Timepoint [2] 461462 0
At patient consultation completion in the pre-admission clinic.
Secondary outcome [3] 461464 0
Evaluation of Patient Satisfaction with the prescribing pharmacist service.
Timepoint [3] 461464 0
Patients completed the survey immediately after their consultation with the prescribing pharmacist in PAC. They were able to complete the survey in a separate area to trial staff and returned their survey anonymously.

Eligibility
Key inclusion criteria
All adult patients attending PAC were eligible for inclusion into the study, subject to providing informed written consent. This also included any patients who may have been followed up by HITH (Hospital in the home) pre or post operatively.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Patients whose primary language was other than English and needed an interpreter
• Diabetic patients who had unstable BSL control
• Patients with unstable cardiac history, including exacerbation of CCF
• Children and/or young people (i.e. < 18 years)
• Patients unwilling or unable (i.e. lacking capacity) to give informed consent
• Pregnant patients or nursing mothers
• Patients who had their surgery cancelled on the day of pre-admission clinic
• Patients who were scheduled to be discharged on the same day as surgery (day patients)
• Not taking any medications at home

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients were randomized for each clinic session using block randomization. Blocks of 5 with opaque envelopes pre-prepared with 0 or 1 (from a random number generator) were opened after patient consent was obtained, and determined whether they entered the control or intervention arm. Administration staff prepared the randomization envelopes. A staff member from the pre-admission clinical or the patient (if a staff member was not available) opened the envelope, and then declared the applicable trial arm. This workflow was employed to avoid any potential perception of bias which might have existed had the pharmacist prescriber opened the envelope.

Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated randomisation sequence.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Patients will be randomised for each clinic session using block randomisation. Blocks of 5 with opaque envelopes pre-prepared with 0 or 1 (from random number generator), to be opened on patient consent, will determine whether they enter the control or intervention arm.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The trial aimed to recruit approximately 122 patients, which hoped to provide for at least 612 prescriptions. This was based on the assumption that each patient had five medications in their home medications list. 612 prescriptions were required for statistical significance. This was an estimate only. Given that little research had been done in this area it was difficult for the statistician to determine the exact sample size required. It was unknown exactly how many patients were admitted to the ward without a complete and accurate medication chart prescribed. Therefore, the sample size was based on previous studies looking at similar pharmacist interventions.

A statistician was engaged to advise on the appropriate parameters required for a statistically robust sample size. For the primary outcome measure, this study was powered for a superiority comparison between the medical model and the doctor-pharmacist collaborative model of care. Using a power of 80%, and an alpha of 0.05, 438 medication orders (219 medication orders in each trial arm) were needed to show a 10% improvement in the intervention trial arm. Given the likely correlation within subjects, this calculation possibly over-estimated the true power of the study. Assuming an interclass correlation coefficient of 0.1, this resulted in a design effect of 1.4. Therefore an inflated sample size of 140% or 612 medication orders (306 medication orders in each trial arm) was required. Assuming an average number of 5 medications per subject, this required recruitment of approximately 61 patients for each trial arm, or 122 patients in total. Unfortunately patient recruitment was restricted and the sample size did not achieve the numbers required to power the data.

The Fischer’s exact test was used to analyse the difference between the two groups for the following results:
• baseline safety process compliance on NIMC
• prescribing errors
• prescribing communication errors
The Fischer’s exact test was chosen due to the fact that all the results for the intervention had a count of less than 10. All p values were two-tailed and calculated using a significance level of 0.05.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29512 0
Redland Hospital - Cleveland
Recruitment postcode(s) [1] 45829 0
4163 - Cleveland

Funding & Sponsors
Funding source category [1] 321822 0
Government body
Name [1] 321822 0
The Allied Health Professions’ Office of Queensland
Country [1] 321822 0
Australia
Primary sponsor type
Hospital
Name
Redland Hospital
Address
Country
Australia
Secondary sponsor category [1] 324680 0
None
Name [1] 324680 0
Address [1] 324680 0
Country [1] 324680 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320365 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 320365 0
Ethics committee country [1] 320365 0
Australia
Date submitted for ethics approval [1] 320365 0
07/07/2015
Approval date [1] 320365 0
20/10/2015
Ethics approval number [1] 320365 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150238 0
Mrs Penelope Garwood-Gowers (nee Richards)
Address 150238 0
Redland Hospital. 21 Weippin St, Cleveland. QLD. 4163.
Country 150238 0
Australia
Phone 150238 0
+61 07 3488 4147
Fax 150238 0
Email 150238 0
Contact person for public queries
Name 150239 0
Penelope Garwood-Gowers (nee Richards)
Address 150239 0
Redland Hospital. 21 Weippin St, Cleveland. QLD. 4163.
Country 150239 0
Australia
Phone 150239 0
+61 07 3488 4147
Fax 150239 0
Email 150239 0
Contact person for scientific queries
Name 150240 0
Penelope Garwood-Gowers (nee Richards)
Address 150240 0
Redland Hospital. 21 Weippin St, Cleveland. QLD. 4163.
Country 150240 0
Australia
Phone 150240 0
+61 07 3488 4147
Fax 150240 0
Email 150240 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Potentially response time and organizational data sharing ;policies



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually

Documents added automatically
No additional documents have been identified.